# Correction: Targeting EGFR/PI3K/AKT/mTOR signaling in lung and colon cancers: synthesis, antitumor evaluation of new 1,2,4-oxdiazoles tethered 1,2,3-triazoles

**Authors:** Mohammed Salah Ayoup, Islam Shawki, Hamida Abdel-Hamid, Doaa A. Ghareeb, Aliaa Masoud, Marwa F. Harras, Mohamed El-Atawy, Nuha Salamah Alharbi, Magda M. F. Ismail

PMC · DOI: 10.1039/d4ra90066a · 2024-06-05

## TL;DR

This paper corrects a previously published study on new compounds targeting cancer-related signaling pathways in lung and colon cancers.

## Contribution

The paper provides corrections to a prior study on the synthesis and evaluation of antitumor compounds.

## Key findings

- The paper identifies errors in the original study's data or methodology.
- It offers revised information to improve the accuracy of the findings.

## Abstract

Correction for ‘Targeting EGFR/PI3K/AKT/mTOR signaling in lung and colon cancers: synthesis, antitumor evaluation of new 1,2,4-oxdiazoles tethered 1,2,3-triazoles’ by Mohammed Salah Ayoup et al., RSC Adv., 2024, 14, 16713–16726, https://doi.org/10.1039/D4RA02222J.

## Linked entities

- **Proteins:** EGFR (epidermal growth factor receptor), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), AKT1 (AKT serine/threonine kinase 1), MTOR (mechanistic target of rapamycin kinase)
- **Diseases:** lung cancer (MONDO:0005138), colon cancer (MONDO:0002032)

## Full-text entities

- **Genes:** AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}
- **Diseases:** lung and colon cancers (MESH:D008175)
- **Chemicals:** 1,2,3-triazoles (-)

---
Source: https://tomesphere.com/paper/PMC11151149